Chronic ketamine reduces the peak frequency of gamma oscillations in mouse prefrontal cortex ex vivo

Frontiers in Psychiatry

Volumn 4, Issue SEP, 2013, Pages

  McNally, James M ^a   McCarley, Robert W ^a   Brown, Ritchie E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Gamma oscillations; Ketamine; NMDA receptors; Prefrontal cortex; Schizophrenia

Indexed keywords

DIZOCILPINE; KAINIC ACID;

ANIMAL EXPERIMENT; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; EX VIVO STUDY; FEMALE; FREQUENCY ANALYSIS; GAMMA BAND OSCILLATION; MALE; MOUSE; NONHUMAN; OSCILLATION; OUTCOME ASSESSMENT; PREFRONTAL CORTEX; SCHIZOPHRENIA;

EID: 84885356564     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2013.00106     Document Type: Article

References (48)

1. Gogolla N, Leblanc JJ, Quast KB, Sudhof TC, Fagiolini M, Hensch TK. Common circuit defect of excitatory-inhibitory balance in mouse models of autism. J Neurodev Disord (2009) 1:172-81. doi:10.1007/s11689-009-9023-x.
2. Woo TU, Spencer K, McCarley RW. Gamma oscillation deficits and the onset and early progression of schizophrenia. Harv Rev Psychiatry (2010) 18:173-89. doi:10.3109/10673221003747609.
3. McNally JM, McCarley RW, Brown RE. Impaired GABAergic neurotransmission in schizophrenia underlies impairments in cortical gamma band oscillations. Curr Psychiatry Rep (2013) 15:346. doi:10.1007/s11920-012-0346-z.
4. Buzsaki G, Draguhn A. Neuronal oscillations in cortical networks. Science (2004) 304:1926-9. doi:10.1126/science.1099745.
5. Uhlhaas PJ, Haenschel C, Nikolic D, Singer W. The role of oscillations and synchrony in cortical networks and their putative relevance for the pathophysiology of schizophrenia. Schizophr Bull (2008) 34:927-43. doi:10.1093/schbul/sbn062.
6. Buzsaki G. Rhythms of the Brain. New York: Oxford University Press (2006).
7. Lewis DA, Gonzalez-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology (2008) 33:141-65. doi:10.1038/sj.npp.1301563.
8. Bubenikova-Valesova V, Horacek J, Vrajova M, Hoschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev (2008) 32:1014-23. doi:10.1016/j.neubiorev.2008.03.012.
9. Corlett PR, Honey GD, Krystal JH, Fletcher PC. Glutamatergic model psychoses: prediction error, learning, and inference. Neuropsychopharmacology (2011) 36:294-315. doi:10.1038/npp.2010.163.
10. Gilmour G, Dix S, Fellini L, Gastambide F, Plath N, Steckler T, et al. NMDA receptors, cognition and schizophrenia-testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology (2012) 62:1401-12. doi:10.1016/j.neuropharm.2011.03.015.
11. Pinault D. N-methyl D-aspartate receptor antagonists ketamine and MK-801 induce wake-related aberrant gamma oscillations in the rat neocortex. Biol Psychiatry (2008) 63:730-5. doi:10.1016/j.biopsych.2007.10.006.
12. Hakami T, Jones NC, Tolmacheva EA, Gaudias J, Chaumont J, Salzberg M, et al. NMDA receptor hypofunction leads to generalized and persistent aberrant gamma oscillations independent of hyperlocomotion and the state of consciousness. PLoS One (2009) 4:e6755. doi:10.1371/journal.pone.0006755.
13. Kittelberger K, Hur EE, Sazegar S, Keshavan V, Kocsis B. Comparison of the effects of acute and chronic administration of ketamine on hippocampal oscillations: relevance for the NMDA receptor hypofunction model of schizophrenia. Brain Struct Funct (2012) 217:395-409. doi:10.1007/s00429-011-0351-8.
14. Anver H, Ward PD, Magony A, Vreugdenhil M. NMDA receptor hypofunction phase couples independent gamma-oscillations in the rat visual cortex. Neuropsychopharmacology (2010) 36:519-28. doi:10.1038/npp.2010.183.
15. McNally JM, McCarley RW, McKenna JT, Yanagawa Y, Brown RE. Complex receptor mediation of acute ketamine application on in vitro gamma oscillations in mouse prefrontal cortex: modeling gamma band oscillation abnormalities in schizophrenia. Neuroscience (2011) 199:51-63. doi:10.1016/j.neuroscience.2011.10.015.
16. Zhang Y, Behrens MM, Lisman JE. Prolonged exposure to NMDAR antagonist suppresses inhibitory synaptic transmission in prefrontal cortex. J Neurophysiol (2008) 100:959-65. doi:10.1152/jn.00079.2008.
17. Xi D, Zhang W, Wang HX, Stradtman GG, Gao WJ. Dizocilpine (MK-801) induces distinct changes of N-methyl-D-aspartic acid receptor subunits in parvalbumin-containing interneurons in young adult rat prefrontal cortex. Int J Neuropsychopharmacol (2009) 12:1395-408. doi:10.1017/S146114570900042X.
18. Vertes RP. Differential projections of the infralimbic and prelimbic cortex in the rat. Synapse (2004) 51:32-58. doi:10.1002/syn.10279.
19. Berman KF, Zec RF, Weinberger DR. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. II. Role of neuroleptic treatment, attention, and mental effort. Arch Gen Psychiatry (1986) 43:126-35. doi:10.1001/archpsyc.1986.01800020032005.
20. Weinberger DR, Berman KF, Zec RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry (1986) 43:114-24. doi:10.1001/archpsyc.1986.01800020020004.
21. Tamamaki N, Yanagawa Y, Tomioka R, Miyazaki J, Obata K, Kaneko T. Green fluorescent protein expression and colocalization with calretinin, parvalbumin, and somatostatin in the GAD67-GFP knock-in mouse. J Comp Neurol (2003) 467:60-79. doi:10.1002/cne.10905.
22. Behrens MM, Ali SS, Dugan LL. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J Neurosci (2008) 28:13957-66. doi:10.1523/JNEUROSCI.4457-08.2008.
23. KeilhoffG, Becker A, Grecksch G, Wolf G, Bernstein HG. Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience (2004) 126:591-8. doi:10.1016/j.neuroscience.2004.03.039.
24. Rujescu D, Bender A, Keck M, Hartmann AM, Ohl F, Raeder H, et al. A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry (2006) 59:721-9. doi:10.1016/j.biopsych.2005.08.029.
25. Behrens MM, Ali SS, Dao DN, Lucero J, Shekhtman G, Quick KL, et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science (2007) 318:1645-7. doi:10.1126/science.1148045.
26. Franklin K, Paxinos G. The Mouse Brain in Stereotaxic Coordinates. New York: Elsevier Press (2008).
27. Irifune M, Sato T, Kamata Y, Nishikawa T, Dohi T, Kawahara M. Evidence for GABA(A) receptor agonistic properties of ketamine: convulsive and anesthetic behavioral models in mice. Anesth Analg (2000) 91:230-6. doi:10.1213/00000539-200007000-00043.
28. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry (2002) 7:837-44. doi:10.1038/sj.mp.4001093.
29. Gray CM, Konig P, Engel AK, Singer W. Oscillatory responses in cat visual cortex exhibit inter-columnar synchronization which reflects global stimulus properties. Nature (1989) 338:334-7. doi:10.1038/338334a0.
30. Rosanova M, Casali A, Bellina V, Resta F, Mariotti M, Massimini M. Natural frequencies of human corticothalamic circuits. J Neurosci (2009) 29:7679-85. doi:10.1523/JNEUROSCI.0445-09.2009.
31. Kwon JS, O'Donnell BF, Wallenstein GV, Greene RW, Hirayasu Y, Nestor PG, et al. Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Arch Gen Psychiatry (1999) 56:1001-5. doi:10.1001/archpsyc.56.11.1001.
32. Vierling-Claassen D, Siekmeier P, Stufflebeam S, Kopell N. Modeling GABA alterations in schizophrenia: a link between impaired inhibition and altered gamma and beta range auditory entrainment. J Neurophysiol (2008) 99:2656-71. doi:10.1152/jn.00870.2007.
33. Spencer KM, Nestor PG, Perlmutter R, Niznikiewicz MA, Klump MC, Frumin M, et al. Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc Natl Acad Sci U S A (2004) 101:17288-93. doi:10.1073/pnas.0406074101.
34. Ferrarelli F, Sarasso S, Guller Y, Riedner BA, Peterson MJ, Bellesi M, et al. Reduced natural oscillatory frequency of frontal thalamocortical circuits in schizophrenia. Arch Gen Psychiatry (2012) 69:766-74. doi:10.1001/archgenpsychiatry.2012.147.
35. Spencer KM, Nestor PG, Niznikiewicz MA, Salisbury DF, Shenton ME, McCarley RW. Abnormal neural synchrony in schizophrenia. J Neurosci (2003) 23:7407-11.
36. Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci (2010) 11:100-13. doi:10.1038/nrn2774.
37. Korotkova T, Fuchs EC, Ponomarenko A, Von Engelhardt J, Monyer H. NMDA receptor ablation on parvalbumin-positive interneurons impairs hippocampal synchrony, spatial representations, and working memory. Neuron (2010) 68:557-69. doi:10.1016/j.neuron.2010.09.017.
38. Carlen M, Meletis K, Siegle JH, Cardin JA, Futai K, Vierling-Claassen D, et al. A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Mol Psychiatry (2012) 17:537-48. doi:10.1038/mp.2011.31.
39. Gandal MJ, Sisti J, Klook K, Ortinski PI, Leitman V, Liang Y, et al. GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction. Transl Psychiatry (2012) 2:e142. doi:10.1038/tp.2012.69.
40. Seillier A, Giuffrida A. Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. Behav Brain Res (2009) 204:410-5. doi:10.1016/j.bbr.2009.02.007.
41. Flood P, Krasowski MD. Intravenous anesthetics differentially modulate ligand-gated ion channels. Anesthesiology (2000) 92:1418-25. doi:10.1097/00000542-200005000-00033.
42. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci (2007) 27:11496-500. doi:10.1523/JNEUROSCI.2213-07.2007.
43. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science (1991) 254:1515-8. doi:10.1126/science.1835799.
44. Spencer KM. The functional consequences of cortical circuit abnormalities on gamma oscillations in schizophrenia: insights from computational modeling. Front Hum Neurosci (2009) 3:33. doi:10.3389/neuro.09.033.2009.
45. Volman V, Behrens MM, Sejnowski TJ. Downregulation of parvalbumin at cortical GABA synapses reduces network gamma oscillatory activity. J Neurosci (2011) 31:18137-48. doi:10.1523/JNEUROSCI.3041-11.2011.
46. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 51:199-214. doi:10.1001/archpsyc.1994.03950030035004.
47. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology (1999) 20:201-25. doi:10.1016/S0893-133X(98)00060-8.
48. Pomarol-Clotet E, Honey GD, Murray GK, Corlett PR, Absalom AR, Lee M, et al. Psychological effects of ketamine in healthy volunteers. Phenomenological study. Br J Psychiatry (2006) 189:173-9. doi:10.1192/bjp.bp.105.015263.